Biodesix announces intent to launch liquid biopsy next generation sequencing test with unprecedented turnaround time

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, has announced their plan to add a blood-based 52-gene next generation sequencing (ngs) test to their portfolio of molecular testing based on a recent publication. of critical importance, the publication, “targeted next-generation sequencing of liquid biopsy samples from patients with nsclc,” in diagnostics showed that the rapid liquid biopsy testing wa
BDSX Ratings Summary
BDSX Quant Ranking